Skip to main content
OpenTrials
Completed

NCT Number: NCT07147985

Effects of Different Exercises on Energy Metabolism and Muscle Activation in Normal-Weight and Overweight Students

This clinical trial aims to investigate the effects of different exercise modalities on energy metabolism and muscle activation in both normal-weight and overweight university students.

The main question it aims to answer is:

Compared to normal-weight university students, does slow jogging at different step frequencies reduce body weight and increase energy expenditure (and metabolic rate) in overweight university students? Compared to normal-weight university students, does slow jogging at different step frequencies enhance muscle activation effects in overweight university students?

Researchers will compare three distinct step frequencies during slow jogging (162, 180, and 198 steps per minute) to determine which exercise modality is potentially more effective for increasing energy expenditure and metabolic rate.

Participants will:

Participants will sequentially undergo three separate testing sessions, each involving ultra-slow running at one of the three step frequencies (162, 180, or 198 steps per minute).

Testing sessions will occur once per week in the laboratory.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Energy Expenditure

Age range

19 year–23 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanxi Normal University

Taiyuan, Shanxi, 030031, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 23 years old;
  • BMI between 24.0 kg/m² and 27.9 kg/m² ;
  • No participation in any structured weight loss or weight control interventions (including exercise programs, pharmacological agents, or dietary regimens) within the preceding three months;
  • Cleared for exercise participation with no identified risks, as determined by the Physical Activity Readiness Questionnaire (PAR-Q);
  • Willing and able to comply fully with the experimental protocol, including completion of all training sessions and required measurements;
  • Provision of written informed consent.

Exclusion criteria

  • History of psychiatric disorders, diabetes mellitus, heart disease, hypertension, anemia, or any other contraindications to exercise (e.g., dizziness, chest pain, shortness of breath);
  • Immune dysfunction or severe hepatic or renal insufficiency;
  • Unhealthy habits, such as regular smoking or excessive alcohol consumption;
  • Current use of prescription medication (excluding contraceptives or incidental short-term medications, if specified and approved by the study investigators);
  • Coagulation disorders or a significant bleeding tendency.

Withdrawal and Termination Criteria:

  • Voluntary withdrawal from the study or discontinuation for any other reason;
  • Poor compliance, defined as failure to follow instructions or complete assigned tasks as required by the protocol;
  • Experiencing severe exercise intolerance or adverse reactions to the intervention.

Treatment and study plan

162 step frequency

Behavioral

The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 162 steps per minute crossover to 180 steps per minute and 198 steps per minute.

180 step frequency

Behavioral

The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 180 steps per minute crossover to 162 steps per minute and 198 steps per minute.

198 step frequency

Behavioral

The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 198 steps per minute crossover to 162 steps per minute and 180 steps per minute.

Primary outcomes

  1. Resting Energy Expenditure (REE)

    Time frame: Baseline

    Subjects abstained from strenuous activity, substances (medication/alcohol/caffeine), and smoking 24h pre-test; females avoided menstruation. Post 12h fast/sleep, subjects rested seated 15min. Resting HR measured (Polar RS400). Subjects fitted with cardiopulmonary telemetry (Cortex Metamax 3B), positioned supine. Maintained steady breathing, upward gaze, minimal movement. HR/V̇O₂ monitored until stabilization. 10min data collection; steady state = <5% V̇O₂ fluctuation over 5min.

  2. Energy Expenditure at Step Frequencies

    Time frame: through study completion, an average of 4 weeks

    Telemetry/HR monitor worn for 3min warm-up. First test: 10min treadmill run (5 km/h) with HR/V̇O₂ recording. Two subsequent sessions followed. Randomized crossover prevented order effects: subjects drew lots for step frequency sequence (162, 180, 198 steps/min). Metronome ensured adherence.

  3. Heart rate

    Time frame: through study completion, an average of 4 weeks

    Upon entering the laboratory, subjects wore a heart rate telemetry monitor (RS400 Polar, Finland) and rested seated for 15 minutes to obtain resting heart rate. Following warm-up, subjects commenced testing. A heart rate monitor was secured on the right wrist pre-exercise to continuously monitor heart rate during activity.

  4. Electromyographic indicators

    Time frame: through study completion, an average of 4 weeks

    Wireless surface EMG data were acquired using the Trigno system (Delsys®, USA) at 2000 Hz. Electrodes were positioned at the mid-belly of each muscle parallel to the muscle fiber orientation. Signals were recorded from the:Biceps femoris、Rectus femoris、Tibialis anterior、Lateral gastrocnemius、Medial gastrocnemius. EMGworks Analysis® software (Delsys) processed raw signals.

Secondary outcomes

  1. Post-Exercise Oxygen Consumption (EPOC)

    Time frame: through study completion, an average of 4 weeks

    EPOC was calculated from pre-/post-exercise oxygen consumption (O₂PRE/O₂POST) measured via portable cardiopulmonary telemetry (Cortex Metamax 3B): EPOC (L) = O₂POST (L) - O₂PRE (L) where: EPOC denotes excess post-exercise oxygen consumption, O₂POST represents post-exercise oxygen consumption, and O₂PRE represents pre-exercise oxygen consumption.

  2. Fat Oxidation

    Time frame: through study completion, an average of 4 weeks

    Fat Oxidation Data were collected and analyzed using the portable cardiopulmonary telemetry system (Cortex Metamax 3B, Germany). The fat oxidation rate was calculated as follows: Fat oxidation rate (g/min) = ② Fat Oxidation Fat oxidation rate was derived as: 1.695 × V̇O₂ (L/min) - 1.701 × V̇CO₂ (L/min) (g/min) using mean V̇O₂/V̇CO₂ from final 2min of each stage. ③ Carbohydrate Oxidation Carbohydrate oxidation rate was calculated as: 4.585 × V̇CO₂ (L/min) - 3.226 × V̇O₂ (L/min) (g/min) using mean V̇O₂/V̇CO₂ from final 2min of each stage. All data collected/analyzed with Cortex Metamax 3B system.

  3. Carbohydrate Oxidation

    Time frame: through study completion, an average of 4 weeks

    Carbohydrate oxidation rate was calculated as: 4.585 × V̇CO₂ (L/min) - 3.226 × V̇O₂ (L/min) (g/min) using mean V̇O₂/V̇CO₂ from final 2min of each stage. All data collected/analyzed with Cortex Metamax 3B system.

  4. RPE

    Time frame: through study completion, an average of 4 weeks

    Immediately after each exercise stage, subjects rated perceived exertion using the Borg RPE scale. The 15-point scale (6-20; 6 = no exertion, 20 = maximal exertion) was administered and recorded post-stage.

Sponsors and collaborators

Lead sponsor

Shanxi Normal University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 29, 2025
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.